On March 4, 2021 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome, reported that 4D management will present at three upcoming investor conferences (Press release, 4d Pharma, MAR 3, 2021, View Source [SID1234576024]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan’s Virtual 3rd Annual Microbiome Medicines Summit: Monday March 8, 2021 at 11:45 am ET (16:45 GMT).
H.C. Wainwright Global Life Sciences Conference: Available on-demand starting Tuesday, March 9, 2021 at 7:00 am ET (12:00 GMT).
Oppenheimer’s 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 8:40 am ET (12:40 GMT).

On March 3, 2021 Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, reported that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021 (Press release, Viracta Therapeutics, MAR 3, 2021, View Source [SID1234576042]). A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. Viracta’s management team will also be available for one-on-one investor meetings at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 3, 2021 Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, reported that it has signed an agreement with the Karolinska Institutet, Stockholm, Sweden (Press release, Oasmia, MAR 3, 2021, View Source [SID1234575986]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will generate new information aiming at the development of new therapeutic APIs. The XR-17 proprietary platform technology enhances intravenous delivery of established and novel drugs in diseases including cancer.

The collaboration will include a review of data and experimental methods to gain a deeper understanding of XR-17 and API formulations in cancer indications with a focus on ovarian carcinoma. This will be followed by an experimental planning phase, which aims to test formulations in suitable systems to generate hypotheses for subsequent evaluation.

Commenting on the collaboration, François Martelet, M.D., Chief Executive Officer of Oasmia, said: "XR-17’s potential to improve drug solubility has been demonstrated by the approval of Apealea for ovarian cancer in Europe, with a second investigational product preparing to enter clinical studies in Switzerland this year. We are delighted to be working with the Karolinska Institutet, one of the most prestigious medical universities and research centers in the world, to further develop our understanding of the potential of this technology in enhancing cancer treatment. Our collaboration with Prof. Rolf Lewensohn and his team at the Department of Oncology-Pathology may lead to the identification of additional applications for the technology and the development of new therapeutics to benefit cancer and other patients."

Prof. Rolf Lewensohn, Principal Investigator at the Karolinska Institutet, Department of Oncology-Pathology, said: "We are looking forward to working with Oasmia on this project. The knowledge and understanding we will be able to generate through this collaboration will help us to better understand the biological properties of XR-17 by defining plasma and target tissue behavior and receptor and transporter affinity. This important work could ultimately enable new study protocols to be drafted."

On March 3, 2021 Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, reported that it has commenced an underwritten public offering of shares of its common stock (Press release, Salarius Pharmaceuticals, MAR 3, 2021, View Source [SID1234576007]). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the public offering.
A shelf registration statement on Form S-3 (File No. 333-231010) relating to the shares was filed with the Securities and Exchange Commission (the "SEC") and was declared effective by the SEC on May 17, 2019. A copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained be obtained at the SEC’s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Attn: Prospectus Department, 640 Fifth Avenue, New York, NY 10019 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On March 3, 2021 TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, reported that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH) (Press release, TrakCel, MAR 3, 2021, View Source [SID1234576025]). These strategic investments enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will use both the investment and the combined expertise gained from collaborations with the investors to further augment its offering to both clinical and commercial-stage cell and gene therapy developers as part of its drive toward industry standardization and future innovation.

TrakCel has developed the broadest portfolio of live deployments in the industry across a range of therapies, from autologous and allogeneic therapies, personalized cancer vaccines and CRISPR, to tumor and marrow infiltrating lymphocyte therapies.

"The close of this funding delivers a unique opportunity to propel the improvement and evolution of our product and services portfolio in order to exceed expectations across the quickly evolving cell and gene therapy space," said Ravi Nalliah, Chief Strategy Officer and Co-Founder, TrakCel. "In addition, this investment enhances our already considerable digital ecosystem of partners. Now, TrakCel has the funding and the partnership support to take advantage of our market and industry experience gained as the first orchestration solution to the cell and gene therapy marketplace."

Augmenting and aligning its digital ecosystem with AmerisourceBergen in the future will allow TrakCel to significantly expand its reach. This will also enable the two companies to offer services that drive them toward further standardization of the delivery of cell and gene therapies.

"The advanced therapy sector is producing major advances in treatment that will revolutionize healthcare and the treatment of diseases with currently limited therapeutic options. It is essential that partners to manufacturers find ways to innovate on behalf of the patient and provider to enhance the treatment experience," said Doug Cook, EVP, President of Commercialization and Animal Health at AmerisourceBergen. "By working with TrakCel, we’ll unlock new ideas and generate new value for all therapy participants, truly living our purpose of creating healthier futures."

Labcorp, a leading global life sciences company, provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Labcorp’s mission to improve health and improve lives will be complemented and supported by TrakCel’s cell, gene and immunotherapy therapy software platform.

"The tools and technologies developed by TrakCel to support the critical needs of advanced therapy logistics are a good complement to the services that we supply for cell and gene therapies," said Steve Anderson, PhD, Chief Scientific Officer, Labcorp Drug Development. "The ability to more effectively orchestrate those activities, paired with Labcorp’s deep scientific and clinical expertise, makes our collaboration an important aspect for the successful delivery and commercialization of advanced therapies. Our investment in TrakCel also further demonstrates our commitment to the area of precision medicine."